Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Lipocine Inc. v. Clarus Therapeutics, Inc.
Case Number:
1:19-cv-00622
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
June 01, 2021
Clarus Wins Ax Of Rival's Testosterone Patent Claims
Clarus Therapeutics Inc. has convinced a federal judge to invalidate claims in four Lipocine Inc. patents that Clarus was accused of infringing with its testosterone replacement treatment Jatenzo, according to an opinion unsealed Tuesday.
-
January 05, 2021
Virus Prompts Delay Of Del. Trial Over Testosterone Drug
The ongoing COVID-19 pandemic has prompted a federal judge to push back the start of a jury trial in Delaware federal court over allegations that a pharmaceutical company's low-testosterone drug infringes patents held by a rival.